ImmVira Completes C Round for Oncolytic Virus and Vector Candidates
December 31, 2020 at 06:37 AM EST
Shenzhen ImmVira completed a Series C financing of undisclosed size. The company focuses on the use of oncolytic viruses and vector approaches for cancer drugs that promise increased safety and efficacy over other types of drug delivery. The company will use the proceeds to fund an international multi-center trial for its lead product (MVR-T3011-IT) plus filing INDs and starting clinical trials for two additional pipeline candidates. In August, ImmVira out-licensed Greater China rights for MVR-T3011 to Shanghai Pharma in an agreement worth up to $176 million. More details.... Share this with colleagues: // //